Sirtris Pharmaceuticals, Inc. (SIRT) is a publicly traded company in the Unknown sector. Across all available filings, 15 corporate insiders have executed 402 transactions totaling $1.9M, demonstrating a bearish sentiment with -$1.9M in net insider flow. The most recent transaction on May 29, 2008 involved a transaction of 81,032 shares valued at $89.1K.
No significant insider buying has been recorded for SIRT in the recent period.
No significant insider selling has been recorded for SIRT in the recent period.
Based on recent SEC filings, insider sentiment for SIRT is bearish with an Insider Alignment Score of 0/100 and a net flow of -$1.9M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Sirtris Pharmaceuticals, Inc. (SIRT) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 15 insiders are actively trading SIRT stock, having executed 402 transactions in the past 90 days. The most active insider is Christoph H. Westphal (Executive), who has made 118 transactions totaling $864.7K.
Get notified when executives and directors at SIRT file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| May 29, 2008 | H. Westphal Christoph | Executive | Option Exercise | 81,032 | $1.10 | $89.1K | |
| May 29, 2008 | H. Westphal Christoph | Executive | Option Exercise | 100,764 | $0.42 | $42.3K | |
| May 28, 2008 | Brannelly Paul | Executive | Option Exercise | 14,643 | $0.42 | $6.2K | |
| May 27, 2008 | Elliott Peter | Executive | Option Exercise | 21,428 | $1.10 | $23.6K | |
| May 27, 2008 | Elliott Peter | Executive | Option Exercise | 74,404 | $0.42 | $31.2K | |
| Apr 11, 2008 | Sinclair David | Executive | Sale | 700 | $13.42 | $9.4K | |
| Apr 11, 2008 | Sinclair David | Executive | Sale | 229 | $13.40 | $3.1K | |
| Apr 11, 2008 | Sinclair David | Executive | Sale | 800 | $13.43 | $10.7K | |
| Apr 11, 2008 | Sinclair David | Executive | Sale | 400 | $13.41 | $5.4K | |
| Apr 11, 2008 | Sinclair David | Executive | Sale | 600 | $12.94 | $7.8K | |
| Apr 11, 2008 | Sinclair David | Executive | Sale | 400 | $12.91 | $5.2K | |
| Apr 11, 2008 | Sinclair David | Executive | Sale | 100 | $13.39 | $1.3K | |
| Apr 11, 2008 | Sinclair David | Executive | Sale | 100 | $13.38 | $1.3K | |
| Apr 11, 2008 | Sinclair David | Executive | Sale | 800 | $13.36 | $10.7K | |
| Apr 11, 2008 | Sinclair David | Executive | Sale | 100 | $13.35 | $1.3K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 350 | $1.9M | 88.8% |
Exercise(M) | 6 | $203.7K | 9.3% |
Award(A) | 15 | $40.7K | 1.9% |
Other(J) | 2 | $0 | 0.0% |
Conversion(C) | 29 | $0 | 0.0% |
Insider selling pressure at Sirtris Pharmaceuticals, Inc. has increased, with 15 insiders executing 402 transactions across all time. Total sales of $1.9M significantly outpace purchases of $0, resulting in a net outflow of $1.9M. This selling activity appears largely discretionary, which may warrant closer attention from investors.